Valuation: Asymchem Laboratories (Tianjin) Co., Ltd.

Market Cap 5.46TCr 812.17Cr 696.03Cr 651.14Cr 595.3Cr 1.12TCr 78TCr 1.14TCr 7.7TCr 3TCr 39TCr 3.05TCr 2.98TCr 1,29200Cr P/E 2026 *
40.6x
P/E 2027 * 31.9x
Enterprise Value 5.03TCr 748.54Cr 641.5Cr 600.13Cr 548.67Cr 1.04TCr 72TCr 1.05TCr 7.1TCr 2.76TCr 36TCr 2.81TCr 2.75TCr 1,19100Cr EV / Sales 2026 *
6.2x
EV / Sales 2027 * 5.18x
Free-Float
61.13%
Yield 2026 *
0.73%
Yield 2027 * 1.14%
Manager TitleAgeSince
Chief Executive Officer 70 07/10/1998
Chief Executive Officer 49 19/01/2022
President - -
Director TitleAgeSince
Director/Board Member 49 18/07/2011
Chairman 70 07/10/1998
Director/Board Member 65 18/07/2011
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 812.17Cr
-0.67%+5.39%+75.21%+127.54% 1,11100Cr
+1.04%+4.07%+52.29%+65.39% 66TCr
-0.17%+5.67%+25.60%+80.40% 47TCr
-0.07%+2.30%+42.05%+42.44% 37TCr
+0.13%+0.92%+25.17%+41.24% 30TCr
+0.50%+2.96%+2.39%+14.03% 26TCr
+1.03%+5.83%+51.11%+72.96% 24TCr
+2.14%+2.89%-16.99%-52.28% 21TCr
+0.42%+5.63%+27.86%+92.24% 18TCr
Average +0.45%+4.49%+31.63%+53.77% 42.12TCr
Weighted average by Cap. +0.21%+4.68%+44.18%+73.20%

Financials

2026 *2027 *
Net sales 811.83Cr 120.75Cr 103.49Cr 97Cr 89Cr 167.03Cr 12TCr 168.8Cr 1.15TCr 445.45Cr 5.81TCr 453.39Cr 443.58Cr 19TCr 971.69Cr 144.53Cr 123.86Cr 115.88Cr 105.94Cr 199.92Cr 14TCr 202.04Cr 1.37TCr 533.17Cr 6.95TCr 542.68Cr 530.93Cr 23TCr
Net income 141.79Cr 21Cr 18Cr 17Cr 15Cr 29Cr 2.02TCr 29Cr 200.08Cr 78Cr 1.01TCr 79Cr 77Cr 3.36TCr 176.74Cr 26Cr 23Cr 21Cr 19Cr 36Cr 2.52TCr 37Cr 249.4Cr 97Cr 1.26TCr 99Cr 97Cr 4.18TCr
Net Debt -427.78Cr -64Cr -55Cr -51Cr -47Cr -88Cr -6.09TCr -89Cr -603.64Cr -234.72Cr -3.06TCr -238.91Cr -233.73Cr -10TCr -428.13Cr -64Cr -55Cr -51Cr -47Cr -88Cr -6.1TCr -89Cr -604.14Cr -234.91Cr -3.06TCr -239.1Cr -233.93Cr -10TCr
Logo Asymchem Laboratories (Tianjin) Co., Ltd.
Asymchem Laboratories Tianjin Co Ltd is a China-based company mainly engaged in providing one-stop comprehensive services for pharmaceutical outsourcing. The Company's business includes customized research and development and production of small molecule drugs (CDMO), chemical macromolecule CDMO, clinical research services, formulation CDMO, biological macromolecule CDMO, technology output and synthetic biology. The Company's product categories cover peptides, oligonucleotides, monoclonal antibodies, antibody-conjugated drugs and messenger RNA. The Company mainly conducts its business in domestic and foreign markets.
Employees
10,617
Trader
Investor
Global
Quality
ESG MSCI
-